Safety and immunogenicity of an AS01-adjuvanted varicella zoster virus subunit candidate vaccine (HZ/su): A phase-I, open-label study in Japanese adults

Human Vaccines and Immunotherapeutics

Volumn 9, Issue 7, 2013, Pages 1425-1429

  Lal, Himal ^a   Zahaf, Toufik ^b   Heineman, Thomas C ^a  

^a GLAXOSMITHKLINE   (United States)

^b GSK   (Belgium)

Author keywords

Adjuvant; Herpes zoster vaccine; Japanese; Reactogenicity; Safety; Varicella zoster virus

Indexed keywords

ENZYGNOST; UNCLASSIFIED DRUG; VARICELLA ZOSTER VACCINE;

ABDOMINAL PAIN; ADULT; ADVERSE OUTCOME; AGED; AUTOIMMUNE DISEASE; AUTOINFLAMMATORY DISEASE; BACKACHE; CHILL; CLINICAL EVALUATION; CONFERENCE PAPER; DIARRHEA; DRUG DOSE REGIMEN; DRUG FATALITY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; GROUPS BY AGE; HERPES ZOSTER; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE SWELLING; JAPANESE; MALE; MYALGIA; NAUSEA AND VOMITING; NORMAL HUMAN; OPEN STUDY; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL; UPPER RESPIRATORY TRACT INFECTION; VACCINATION REACTION; VACCINE FAILURE;

ADJUVANT; HERPES ZOSTER VACCINE; JAPANESE; REACTOGENICITY; SAFETY; VARICELLA-ZOSTER VIRUS;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; AGED; ANTIBODIES, VIRAL; ANTIBODY FORMATION; FEMALE; HERPES ZOSTER; HERPES ZOSTER VACCINE; HERPESVIRUS 3, HUMAN; HUMANS; JAPAN; MALE; MIDDLE AGED; VACCINATION; VACCINES, SUBUNIT; VIRAL ENVELOPE PROTEINS; YOUNG ADULT;

EID: 84880870892     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.24269     Document Type: Conference Paper

References (21)

1. Eshleman E, Shahzad A, Cohrs RJ. Varicella zoster virus latency. Future Virol 2011; 6:341-55; PMID:21695042.
2. Varicella vaccines. WHO position paper. Wkly Epidemiol Rec 1998; 73:241-8; PMID:9715106.
3. Toyama N, Shiraki K; Society of the Miyazaki Prefecture Dermatologists. Epidemiology of herpes zoster and its relationship to varicella in Japan: A 10-year survey of 48,388 herpes zoster cases in Miyazaki prefecture. J Med Virol 2009; 81:2053-8; PMID:19856466.
4. Chapman RS, Cross KW, Fleming DM. The incidence of shingles and its implications for vaccination policy. Vaccine 2003; 21:2541-7; PMID:12744889.
5. Gonzalez Chiappe S, Sarazin M, Turbelin C, Lasserre A, Pelat C, Bonmarin I, et al. Herpes zoster: Burden of disease in France. Vaccine 2010; 28:7933-8; PMID:20946861.
6. Yawn BP, Saddier P, Wollan PC, St Sauver JL, Kurland MJ, Sy LS. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc 2007; 82:1341-9; PMID:17976353.
7. Harpaz R, Ortega-Sanchez IR, Seward JF; Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008; 57(RR-5):1-30, quiz CE2-4; PMID:18528318.
8. Gershon AA, Gershon MD, Breuer J, Levin MJ, Oaklander AL, Griffiths PD. Advances in the understanding of the pathogenesis and epidemiology of herpes zoster. J Clin Virol 2010; 48(Suppl 1):S2-7; PMID:20510263.
9. Schmader KE, Levin MJ, Gnann JW Jr., McNeil SA, Vesikari T, Betts RF, et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. Clin Infect Dis 2012; 54:922-8; PMID:22291101.
10. Murray AV, Reisinger KS, Kerzner B, Stek JE, Sausser TA, Xu J, et al. Safety and tolerability of zoster vaccine in adults ≥ 60 years old. Hum Vaccin 2011; 7:1130-6; PMID:22048110.
11. Sampathkumar P, Drage LA, Martin DP. Herpes zoster (shingles) and postherpetic neuralgia. Mayo Clin Proc 2009; 84:274-80; PMID:19252116.
12. Andrei G, Snoeck R. Emerging drugs for varicellazoster virus infections. Expert Opin Emerg Drugs 2011; 16:507-35; PMID:21699441.
13. Oxman MN. Zoster vaccine: current status and future prospects. Clin Infect Dis 2010; 51:197-213; PMID:20550454.
14. Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, et al.; Shingles Prevention Study Group. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005; 352:2271-84; PMID:15930418.
15. Garçon N, Chomez P, Van Mechelen M. GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives. Expert Rev Vaccines 2007; 6:723-39; PMID:17931153.
16. Garçon N, Van Mechelen M. Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems. Expert Rev Vaccines 2011; 10:471-86; PMID:21506645.
17. Grose C. Glycoproteins encoded by varicella-zoster virus: biosynthesis, phosphorylation, and intracellular trafficking. Annu Rev Microbiol 1990; 44:59-80; PMID:2174668.
18. Grahn A, Studahl M, Nilsson S, Thomsson E, Bäckström M, Bergström T. Varicella-zoster virus (VZV) glycoprotein E is a serological antigen for detection of intrathecal antibodies to VZV in central nervous system infections, without cross-reaction to herpes simplex virus 1. Clin Vaccine Immunol 2011; 18:1336-42; PMID:21697341.
19. Leroux-Roels I, Leroux-Roels G, Clement F, Vandepapelière P, Vassilev V, Ledent E, et al. A phase 1/2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein e subunit vaccine candidate in young and older adults. J Infect Dis 2012; 206:1280-90; PMID:22872734.
20. Chlibek R, Smetana J, Pauksens K, Van den Hoek A, Richardus JH, Wachter J, et al. Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults. Presented at the 37th Annual International Herpesvirus Workshop (IHW), Canada, August 4-9, 2012. Available at: http://www.herpesvirusworkshop.com/2012/. Accessed: November 2nd, 2012.
21. Clark TG, Cassidy-Hanley D. Recombinant subunit vaccines: potentials and constraints. Dev Biol (Basel) 2005; 121:153-63; PMID:15962478.